Renal sympathetic denervation reduces left ventricular hypertrophy and improves cardiac function in patients with resistant hypertension.

[1]  H. Krum,et al.  Sympatho-renal axis in chronic disease , 2011, Clinical Research in Cardiology.

[2]  H. Krum,et al.  Effect of Renal Sympathetic Denervation on Glucose Metabolism in Patients With Resistant Hypertension: A Pilot Study , 2011, Circulation.

[3]  H. Krum,et al.  Device-Based Antihypertensive Therapy: Therapeutic Modulation of the Autonomic Nervous System , 2011, Circulation.

[4]  M. Volpe,et al.  [The progression from hypertension to congestive heart failure]. , 2011, Recenti progressi in medicina.

[5]  H. Krum,et al.  Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial , 2010, The Lancet.

[6]  F. Cuccurullo,et al.  RELATIONSHIP BETWEEN METABOLIC SYNDROME AND LEFT VENTRICULAR REMODELING: INFLUENCE OF GENDER: PP.22.356 , 2010, American journal of hypertension.

[7]  A. M. Leone,et al.  Why beta-blockers should not be used as first choice in uncomplicated hypertension. , 2010, The American journal of cardiology.

[8]  E. Muxfeldt,et al.  Prognostic impact of baseline and serial changes in electrocardiographic left ventricular hypertrophy in resistant hypertension. , 2010, American heart journal.

[9]  J. S. Janicki,et al.  Sympathetic Nervous System Modulation of Inflammation and Remodeling in the Hypertensive Heart , 2010, Hypertension.

[10]  W. J. Elliott,et al.  Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study , 2010 .

[11]  H. Krum,et al.  Renal sympathetic-nerve ablation for uncontrolled hypertension. , 2009, The New England journal of medicine.

[12]  G. Mancia,et al.  Left ventricular hypertrophy increases cardiovascular risk independently of in-office and out-of-office blood pressure values , 2009, Journal of hypertension.

[13]  Arturo Evangelista,et al.  Recommendations for the evaluation of left ventricular diastolic function by echocardiography. , 2009, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[14]  L. Ruilope,et al.  Left ventricular hypertrophy and clinical outcomes in hypertensive patients. , 2008, American journal of hypertension.

[15]  A. Pose-Reino,et al.  Deberían los bloqueadores beta permanecer en la primera línea del tratamiento de la hipertensión arterial esencial , 2007 .

[16]  Alice Stanton,et al.  Differential Impact of Blood Pressure–Lowering Drugs on Central Aortic Pressure and Clinical Outcomes: Principal Results of the Conduit Artery Function Evaluation (CAFE) Study , 2006, Circulation.

[17]  Richard B Devereux,et al.  Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardio , 2005, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[18]  G. Palladini,et al.  Sympathectomy or Doxazosin, But Not Propranolol, Blunt Myocardial Interstitial Fibrosis in Pressure-Overload Hypertrophy , 2005, Hypertension.

[19]  L. Lindholm,et al.  Should β blockers remain first choice in the treatment of primary hypertension? A meta-analysis , 2005, The Lancet.

[20]  R. Devereux,et al.  Cardiovascular Morbidity and Mortality in Hypertensive Patients With Lower Versus Higher Risk: A LIFE Substudy , 2005, HYPERTENSION.

[21]  M. Nieminen,et al.  Prognostic significance of left ventricular mass change during treatment of hypertension. , 2004, JAMA.

[22]  M. Nieminen,et al.  Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. , 2004, JAMA.

[23]  F. Magrini,et al.  Different Effects of Antihypertensive Therapies Based on Losartan or Atenolol on Ultrasound and Biochemical Markers of Myocardial Fibrosis: Results of a Randomized Trial , 2004, Circulation.

[24]  R. Schmieder,et al.  A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. , 2003, The American journal of medicine.

[25]  Douglas W Mahoney,et al.  Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. , 2003, JAMA.

[26]  Arantxa González,et al.  Losartan-Dependent Regression of Myocardial Fibrosis Is Associated With Reduction of Left Ventricular Chamber Stiffness in Hypertensive Patients , 2002, Circulation.

[27]  M. Nieminen,et al.  For Personal Use. Only Reproduce with Permission from the Lancet Publishing Group , 2022 .

[28]  P. Weidmann,et al.  Diastolic dysfunction precedes myocardial hypertrophy in the development of hypertension. , 2001, American journal of hypertension.

[29]  R. Devereux,et al.  Impact of different partition values on prevalences of left ventricular hypertrophy and concentric geometry in a large hypertensive population : the LIFE study. , 2000, Hypertension.

[30]  G. Grassi,et al.  Sympathetic activation in the pathogenesis of hypertension and progression of organ damage. , 1999, Hypertension.

[31]  S. Vatner,et al.  β-Adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic Gsα mouse , 1999 .

[32]  S. Vatner,et al.  Beta-adrenergic receptor blockade arrests myocyte damage and preserves cardiac function in the transgenic G(salpha) mouse. , 1999, The Journal of clinical investigation.

[33]  G. Dibona,et al.  Neural control of renal function. , 1997, Physiological reviews.

[34]  N. Chang,et al.  Patterns of isolated septal hypertrophy and their clinical correlations in essential hypertension , 1996 .

[35]  G. Schillaci,et al.  Asymmetric left ventricular remodeling due to isolated septal thickening in patients with systemic hypertension and normal left ventricular masses. , 1994, The American journal of cardiology.

[36]  W. Kannel,et al.  Left ventricular hypertrophy as a risk factor in arterial hypertension. , 1992, European heart journal.

[37]  K. Pennert,et al.  Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. , 1992, American journal of hypertension.

[38]  J. Laragh,et al.  Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. , 1991, Annals of internal medicine.

[39]  B. Tallant,et al.  Hypertrophy, fibrosis and diastolic dysfunction in early canine experimental hypertension. , 1991, Journal of the American College of Cardiology.

[40]  D. Levy,et al.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. , 1990, The New England journal of medicine.

[41]  R. O’rahilly,et al.  Book ReviewNeuroanatomy: An atlas of structures, sections and systems , 1987 .

[42]  Mosteller Rd.  Simplified Calculation of Body-Surface Area , 1987 .

[43]  N. Reichek,et al.  Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. , 1986, The American journal of cardiology.

[44]  B. Massie,et al.  Abnormal left ventricular filling: an early finding in mild to moderate systemic hypertension. , 1984, The American journal of cardiology.